NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from EHZ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
+3 more ↓
68%
Finnrick rating
#337 of 498 ranked vendors
56 of 75 classifiable tests passed
methodology · Purity focus
Finnrick analysis

EHZ Peptides' strongest purity-focus evidence is in Retatrutide and Tirzepatide, with recent mostly high-purity, in-fill results but a few identity, purity, and fill misses. The record is dispersed: GHK-Cu recovered after a zero/identity failure, while BPC-157 is mixed and Tesamorelin/Cagrilintide are failure-heavy; batch traceability is often thin.

methodology →
vendor intelligence report
Vendor Intelligence Report: EHZ Peptides

The report follows a verified Google Ads identity into a California LLC lead, while separating that commercial trail from unresolved beneficial ownership. It also documents COA overlays, Brown Biology verification gaps, and a Nanjing channel check that does not clear EHZ.

33 pages6 risk factors assessed11 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Retatrutide
$0.63
86%
36
2
Tirzepatide
$0.50
83%
16
3
GHK-Cu
$0.04
81%
7
4
BPC-157
$0.55
50%
6
5
Cagrilintide
$2.10
50%
3
6
Tesamorelin
$1.55
37%
7
7
HGH
$0.53
-
0
8
Ipamorelin
$0.65
-
0
9
MOTS-c
$0.80
-
0
10
TB-500
$1.15
-
0
11
Wolverine
$0.88
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%26 Jan 2026: 66%26 Jan 2026: 66%26 Jan 2026: 66%4 Feb 2026: 65%9 Feb 2026: 65%10 Feb 2026: 65%10 Feb 2026: 65%10 Feb 2026: 65%10 Feb 2026: 65%15 Feb 2026: 66%18 Feb 2026: 66%20 Feb 2026: 66%20 Feb 2026: 66%20 Feb 2026: 66%4 Mar 2026: 67%6 Mar 2026: 68%6 Mar 2026: 68%6 Mar 2026: 68%6 Mar 2026: 68%28 Apr 2026: 68%16 Jun 2026: 68%13 Jul 2026: 69%13 Jul 2026: 69%13 Jul 2026: 69%13 Jul 2026: 70%17 Jul 2026: 70%21 Jul 2026: 69%6 Aug 2026: 70%7 Sep 2026: 70%9 Sep 2026: 70%9 Sep 2026: 69%10 Sep 2026: 69%14 Sep 2026: 69%17 Sep 2026: 69%30 Sep 2026: 69%1 Oct 2026: 69%5 Oct 2026: 69%6 Oct 2026: 68%8 Oct 2026: 68%23 Oct 2026: 68%12 Nov 2026: current 68%66%68%68%Jan 26Nov 26
Peptide testing

Ordered peptides from EHZ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
EHZ Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
23 Oct 2026
Pass
Retatrutide
lab nameView COA
8 Oct 2026
Fail
Cagrilintide
lab nameView COA
6 Oct 2026
Fail
Retatrutide
lab nameView COA
5 Oct 2026
Fail
Tesamorelin
lab nameView COA
1 Oct 2026
Pass
Tirzepatide
lab nameView COA
30 Sep 2026
Pass
Retatrutide
lab nameView COA
17 Sep 2026
Fail
Retatrutide
lab nameView COA
14 Sep 2026
Pass
Retatrutide
lab nameView COA
10 Sep 2026
Fail
Tesamorelin
lab nameView COA
9 Sep 2026
Fail
GHK-Cu
lab nameView COA
1-10 of 75

About EHZ Peptides test results from Finnrick

EHZ Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 6 peptides and 75 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible EHZ Peptides peptides in this dataset are BPC-157 (6 tests), Cagrilintide (3 tests) and GHK-Cu (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 75 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from EHZ Peptides? Mail in a sample (US only) and let us test it.

Test my supply